Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571619 · ClinicalTrials.gov registry record · Phase 2
HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 643
- Enrollment target
NCT04571619 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 643 participants.
The verdict
NCT04571619, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 643 participants
- Enrollment target
Study Summary
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine will be acceptable and tolerable as an approach to managing physical dependence on opioids in this patient population.
Interventions
- DRUG Buprenorphine
- BEHAVIORAL Pain Coping Skills Training (PCST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2021-01-03 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04571619
The ClinicalTrials.gov registry entry for NCT04571619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine is the first listed.
NCT04571619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04571619 about?
NCT04571619 is a clinical study titled "HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis". HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid ...
What is the current status of trial NCT04571619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 643 participants. The study started on 2021-01-03. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04571619?
The interventions under investigation include: Buprenorphine (DRUG), Pain Coping Skills Training (PCST) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04571619?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.